Evolving treatment landscape: 18 years of managing melanoma in a single patient.

cancer intervention healthcare improvement and patient safety malignant disease and immunosuppression skin cancer surgical oncology

Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
02 Nov 2021
Historique:
entrez: 3 11 2021
pubmed: 4 11 2021
medline: 5 11 2021
Statut: epublish

Résumé

A 57-year-old woman diagnosed with primary melanoma was managed with a wide variety of treatments over 18 years. Given her long history of disease, the array of therapies she has received range from those no longer recommended to those recently approved. This case highlights the extraordinary rate at which both the medical and surgical melanoma treatment landscape has evolved, alongside how professional consensus has changed over the past two decades. It also demonstrates the innovation and collaboration required between the patient and the multidisciplinary team, as well as how external factors such as national guidelines, eligibility for clinical trials and drug funding in the National Health Service (NHS) alter a management plan, presenting yet another set of challenges when managing cancer patients in the modern era.

Identifiants

pubmed: 34728513
pii: 14/11/e246070
doi: 10.1136/bcr-2021-246070
pmc: PMC8565563
pii:
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Cancers (Basel). 2021 Jun 11;13(12):
pubmed: 34208218
N Engl J Med. 2006 Sep 28;355(13):1307-17
pubmed: 17005948
Lancet. 1998 Mar 14;351(9105):793-6
pubmed: 9519951
N Engl J Med. 2021 Jun 10;384(23):2229-2240
pubmed: 34107182
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
Lancet Oncol. 2016 Jun;17(6):757-767
pubmed: 27161539
Clin Cancer Res. 2004 Mar 1;10(5):1670-7
pubmed: 15014018
J Clin Oncol. 1996 Oct;14(10):2666-73
pubmed: 8874325
Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5
pubmed: 10522715
Ther Adv Med Oncol. 2014 Nov;6(6):262-6
pubmed: 25364391
Lancet Oncol. 2020 Nov;21(11):1394-1395
pubmed: 32961120

Auteurs

Garance Biosse-Duplan (G)

University of Cambridge School of Clinical Medicine, Cambridge, UK garance.biosseduplan@addenbrookes.nhs.uk.

Suzanne Murphy (S)

Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge, UK.

Amer Durrani (A)

Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge, UK.

Pippa Corrie (P)

Department of Oncology, Addenbrooke's Hospital, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH